Pharmacist-led olaparib follow-up service for ambulatory ovarian cancer patients: A prospective study in a tertiary specialized cancer hospital in China

• DOI: 10.3389/fphar.2022.1037726
• Publication Date: 2022-12-13T16:47:59Z
• Authors: Yanting Wang; Di Du; Jun Yang; Alan H. Lau; Yuanyuan Dai; Wangjun Qin; Ning Li; Guohui Li
• Keywords: Olaparib; Tolerability; Concomitant

Purpose: To establish a pharmacist-led olaparib follow-up program for ovarian cancer patients, provide patient education, get information on adverse drug reactions (ADRs), and identify manage drug-related problems. Methods: Ambulatory adult patients with receiving were enrolled. At least one session was conducted by clinical pharmacists. Pharmacists collected data the type grade of ADRs, adherence, dosing, concomitant medications, pharmacists' suggestions. Results: 83 enrolled median age 58. The average number sessions provided to each 1.31, duration 17.78 min. starting dose most (97.59%) 600 mg/d. 36.14% had missed doses 27.71% adjustments due ADRs. common ADRs (incidence≥10%) were: fatigue (40.96%), anemia (36.14%), leukopenia nausea (28.92%), thrombocytopenia (16.87%), anorexia dyspepsia (15.66%). tolerability profiles generally similar between treated "first-line maintenance" those "recurrence (p > .05). There 42% who concomitantly taking medications without exact chemical contents (such as formulated Chinese medicines decoctions), types names antihypertensive, anti-hyperglycemic, anti-hyperlipidemic medications. pharmacists identified 4 clinically significant drug-drug interactions (DDIs) in two patients. made 196 suggestions mainly related rational use management Conclusion: study provides first report about service olaparib. previously observed trials, different (first-line maintenance vs. recurrence maintenance) also similar. problems DDIs ADRs) offer